Cachexia is a muscle-wasting syndrome that has a 50% overall prevalence across all cancers and is known to affect both survival and quality of life. However, its measurement, classification, and impact in individuals with primary brain tumors is unclear. Now, evidence is emerging that cachexia has a direct effect on both clinical and physical function outcomes for individuals with glioblastoma multiforme (GBM). Herein, we outline a standardized approach to the diagnosis of cachexia in the GBM population, incorporating several available clinical tools to ensure the link between clinical prognosis and quality of life.
Kelly et al. (Wed,) studied this question.